Phase III trials

Related by string. Phase III Trial * phase . phases . Phases . PHASE : Phase III clinical trials . Phase III clinical . pivotal Phase III . Phase 2b clinical / iii . Iii . IIIs . IIID : Star Wars Episode III . Guitar Hero III . Tha Carter III . Mission Impossible III / Trial . trialed . trialing . Trials : Week Premium Trial . randomized controlled trial . randomized controlled trials . Team Trials * *

Related by context. All words. (Click for frequent words.) 81 Phase III clinical trials 79 clinical trials 78 Phase IIb trial 77 Phase III clinical 76 Phase III 76 clinical trial 75 phase IIa 74 Phase 2b study 74 Phase IIa trial 74 Phase IIb trials 73 phase IIb 73 Phase 2b trial 73 pivotal Phase III 73 Phase IIb 71 Phase Ib 70 Phase 2a trial 70 phase IIa clinical 70 phase IIb trial 69 Phase IIa trials 69 Phase 1b trial 69 Phase 2b 69 Phase IIa 69 Phase IIb clinical trials 69 midstage studies 68 Phase 2b clinical 68 Phase IIb clinical 68 phase IIb clinical 68 Phase 2a 67 Phase IIa clinical 67 Phase Ib clinical 66 registrational 66 Phase IIIb clinical 66 Phase III pivotal 66 Phase Ib study 66 confirmatory Phase III 66 midstage trials 66 Phase 2b clinical trials 66 Phase 2a clinical 65 pivotal Phase 65 mipomersen 65 preclinical 65 Corlux 65 Phase #b/#a 65 dirucotide 65 clinical pharmacology studies 65 HuMax CD# 64 Phase III Clinical Trials 64 JAK inhibitor 64 GALNS 64 Phase 1b clinical 64 phase Ib 64 phase IIb study 64 Phase IIa clinical trials 63 phase 2a 63 registrational trial 63 teduglutide 63 Asentar 63 preclinical studies 63 confirmatory Phase 3 63 Phase II 63 daclizumab 63 phase Ib clinical 63 dose escalation Phase 63 Phase Ib clinical trials 63 placebo controlled clinical trials 63 placebo controlled Phase 62 Phase 1b 62 bicifadine 62 PRX # 62 randomized clinical trials 62 BLA filing 62 placebo controlled clinical 62 PREOS 62 tivozanib 62 cannabinor 62 OvaRex ® MAb 62 Urocidin 62 Icatibant 62 axitinib 62 Phase 1a 62 ocrelizumab 62 dose escalation 62 Amrubicin 62 Plicera 62 MBP# [001] 62 SUCCEED trial 62 EOquin 62 rALLy trial 61 Phase IIB 61 randomized Phase 61 diabetic neuropathic pain 61 Fodosine 61 Phase Ib II 61 Phase IIIb study 61 dose cohorts 61 placebo controlled studies 61 Mipomersen 61 HuMax CD4 61 oral ridaforolimus 61 multicenter Phase 61 BAY #-# 61 Dacogen injection 61 pharmacokinetic studies 61 ruxolitinib 61 GLP toxicology studies 61 CDP# 61 PSN# [002] 61 Orazol 61 Phase #/#a 61 AEG# 61 dose escalation trial 61 Flutiform 61 Viramidine 61 elagolix 61 integrase inhibitor 61 Allovectin 7 61 TELINTRA 61 GSK# [002] 61 Amigal 61 pivotal bioequivalence 61 IIa trial 61 Relovair 61 Phase IIIb 61 tolevamer 61 IND enabling 61 placebo controlled Phase III 61 HGS# 61 Phase Ia 61 pradefovir 61 TELCYTA 61 StaphVAX 61 midstage clinical trial 61 Oglemilast 60 Lupuzor 60 INCB# [001] 60 Bronchitol 60 COMFORT II 60 Omigard 60 ASA# 60 liprotamase 60 alogliptin 60 rEV# 60 dosing cohorts 60 tezampanel 60 BCX# 60 PEG PAL 60 midstage study 60 ozarelix 60 midstage clinical trials 60 bendamustine 60 VEGF Trap 60 dalbavancin 60 forodesine 60 NDA submission 60 active comparator 60 ganetespib 60 Marqibo 60 almorexant 60 multicenter Phase II 60 Canvaxin 60 SNT MC# 60 T DM1 60 multicenter clinical 60 incyclinide 60 randomized Phase IIb 60 AZILECT ® 60 enzastaurin 60 elotuzumab 60 Firazyr 60 RSD# oral 60 Reverset 60 HuMax EGFr 60 investigational compound 60 faropenem 60 valopicitabine 60 IND submission 60 Nexavar sorafenib 60 pertuzumab 60 arzoxifene 60 Bydureon 60 Ceplene 60 cangrelor 59 obatoclax 59 Phenoptin 59 PDE4 inhibitor 59 placebo controlled trials 59 deforolimus 59 Factor VIIa 59 Santhera 59 CCR5 antagonist 59 MAA submission 59 bapineuzumab 59 Phase III randomized controlled 59 RhuDex ® 59 NO# [002] 59 Fx #A 59 Allovectin 7 R 59 teriflunomide 59 Antegren 59 Clinical trials 59 Telaprevir 59 NGX# 59 alvespimycin 59 ProLindac 59 investigational drug 59 AQ4N 59 picoplatin 59 Flutiform TM 59 EndoTAG TM -1 59 Torisel 59 EpiCept NP 1 59 ProSavin 59 Desmoteplase 59 Phase 2a clinical trials 59 lomitapide 59 Phase III Clinical Trial 59 Nasulin 59 MyVax 59 Memryte 59 BLA submission 59 Rezular 59 placebo controlled 59 pharmacokinetic 59 IMA# 59 nonclinical studies 59 ENDEAVOR IV 59 bazedoxifene 59 omacetaxine mepesuccinate 59 PRT# 59 multicenter trials 59 bardoxolone 59 Actemra 59 ITAX 59 Ocrelizumab 59 tremelimumab 59 carfilzomib 59 randomized Phase III 59 alvimopan 59 anidulafungin 59 budesonide foam 59 IMGN# 59 telaprevir 59 AZILECT R 59 superficial bladder cancer 59 Sutent sunitinib 59 Nebido 59 Pivotal Trial 59 viral kinetic 59 Tocosol Paclitaxel 59 KRN# 59 omacetaxine 59 HCV SPRINT 59 dose cohort 59 mertansine 59 trastuzumab DM1 59 Xyotax 59 KNS # 59 Preos 59 BrachySil 59 Civacir 59 RG# [001] 58 cetrorelix 58 taspoglutide 58 opioid induced bowel dysfunction 58 eltrombopag 58 Varisolve 58 TMC# [002] 58 Loramyc R 58 Viprinex 58 BEMA TM Fentanyl 58 oral deforolimus 58 multicenter randomized placebo controlled 58 BRIM3 58 Zerenex 58 Zalbin 58 eprotirome 58 ANCHOR trial 58 reslizumab 58 PREOS R 58 vosaroxin 58 DR Cysteamine 58 olaparib 58 SinuNase TM 58 Dacogen 58 TBC# 58 Gabapentin GR 58 Erbitux cetuximab 58 Acapodene 58 Pirfenidone 58 Zytiga 58 YONDELIS 58 Aryplase 58 randomized controlled clinical trials 58 Diamyd ® 58 EOquin TM 58 Alzhemed TM 58 Phase #b/#a trial 58 ixabepilone 58 Ereska 58 generation purine nucleoside 58 betrixaban 58 Gattex 58 MAXY alpha 58 Zensana 58 Kynapid 58 INDs 58 PROMACTA 58 Allovectin 7 ® 58 OvaRex R 58 ularitide 58 efficacy endpoint 58 AzaSite Plus 58 OMAPRO 58 dexpramipexole 58 Zolinza 58 dose escalation study 58 Cimzia 58 Vectibix panitumumab 58 Laquinimod 58 rALLy clinical trial 58 HCV RESPOND 2 58 candidates Dyloject TM 58 Adlea 58 carcinogenicity study 58 VA# [002] 58 Trexima 58 MIRCERA 58 phase IIIb 58 LY# [003] 58 MOZOBIL 58 SYMMETRY trial 58 randomized trials 58 GLPG# 58 BRAF inhibitor 58 Cladribine 58 Cimzia TM 58 Bicifadine 58 Voraxaze 58 antibody MAb 58 double blinded placebo 58 Heplisav 58 TOCOSOL Paclitaxel 58 Archexin 58 APTIVUS 58 Hyphanox 58 Nuvion 58 afamelanotide 58 Sym# 58 IMC A# 58 clofarabine 58 OHR/AVR# 58 Alpharadin 57 vilazodone 57 Darusentan 57 brivaracetam 57 CoFactor 57 oral formulation 57 solanezumab 57 ponatinib 57 Dyloject 57 Tyrima 57 PFO migraine 57 PF # [002] 57 Phase 1a clinical 57 Annamycin 57 Riquent 57 AP# [003] 57 miconazole Lauriad ® 57 apaziquone 57 Arcalyst 57 CB2 selective receptor agonist 57 Panzem R NCD 57 dose escalation clinical 57 #D#C# 57 initiate Phase IIb 57 FOLOTYN ® 57 oral prodrug 57 MGCD# [001] 57 GAMMAGARD 57 mapatumumab 57 NVA# 57 goserelin 57 IDX# 57 ADVANCE PD 57 tamibarotene 57 sunitinib malate 57 Quinamed 57 multiple ascending dose 57 Proxinium TM 57 LibiGel Phase III 57 Ixempra 57 Daclizumab 57 investigational 57 baminercept 57 aclidinium 57 Velcade bortezomib 57 rilpivirine 57 cetuximab Erbitux 57 orBec 57 Ostarine 57 Lu AA# 57 Acetavance 57 aflibercept 57 DU #b 57 multicenter phase 57 glufosfamide 57 lumiliximab 57 Leukine 57 INCB# [002] 57 investigational protease inhibitor 57 OncoVEX GM CSF 57 adipiplon 57 severe hypercholesterolemia 57 blinatumomab 57 confirmatory Phase 57 DPP4 inhibitor 57 zalutumumab 57 Zensana TM 57 elacytarabine 57 panitumumab 57 Marketing Authorization Application 57 Abraxane 57 ADX# 57 figitumumab 57 atrasentan 57 PTK ZK 57 virus HCV protease inhibitor 57 Kuvan 57 placebo controlled randomized 57 OncoVEX 57 Juvista 57 randomized controlled Phase 57 Tamibarotene 57 PXD# 57 Aflibercept 57 LymphoStat B 57 ofatumumab 57 PrevOnco 57 lurasidone 57 Glybera 57 RELOVAIR ™ 57 Triolex 57 lixisenatide 57 R#/MEM # 57 isavuconazole 57 Menerba 57 docetaxel Taxotere ® 57 oral taxane 57 dose regimens 57 Elagolix 57 vicriviroc 57 personalized immunotherapy 57 apricitabine 57 dexanabinol 57 LUMINATE 57 pharmacokinetic PK study 57 iniparib 57 huC# DM4 57 RezularTM 57 Alocrest 57 SinuNase 57 ATL# [001] 57 Actemra tocilizumab 57 ridaforolimus 57 pegloticase 57 T Pred 57 CR# vcMMAE 57 Ozarelix 57 APEX PD 57 multicenter Phase III 57 ICA # 57 Treanda 57 sapacitabine 57 Phase III randomized 57 Omapro 57 ISIS # 57 midstage clinical 57 confirmatory clinical 57 EFAPROXYN 57 Fablyn 57 MyVax personalized immunotherapy 57 HspE7 57 randomized controlled 57 oral calcitonin 57 maraviroc 57 Phase #/#a trial 57 ocular formulation 57 telcagepant 57 AEGR 57 Entereg 57 pitavastatin 57 metastatic hormone refractory 57 avanafil 57 Marketing Authorisation Application 57 Onrigin 57 rindopepimut 57 tanespimycin 57 ENRICH trial 57 albinterferon alfa 2b 57 PEP# [003] 57 Milnacipran 57 metastatic sarcomas 57 ataluren 57 Telcyta 57 riociguat 57 octreotide implant 56 randomized placebo controlled 56 danoprevir 56 Tarceva TM 56 Synavive 56 edoxaban 56 NP2 Enkephalin 56 glatiramer acetate 56 Zenvia Phase III 56 seliciclib CYC# 56 unblind 56 Evoltra TM 56 Pivotal Phase 56 vismodegib 56 otelixizumab 56 LCP AtorFen 56 randomized multicenter 56 DXL# 56 asenapine 56 randomized clinical 56 DSMB 56 tecarfarin 56 ADAGIO study 56 Advagraf 56 Aurora kinase inhibitor 56 OvaRex 56 tezampanel NGX# 56 Cetrorelix 56 Investigational 56 IL# PE#QQR 56 Ventavis 56 Abiraterone 56 LIVALO 56 Exherin TM 56 Genentech Roche 56 neratinib 56 Safinamide 56 Firdapse 56 Certriad 56 APF# 56 pomalidomide 56 ATryn ® 56 ustekinumab 56 GRN# 56 investigational pan BCR 56 Frova ® 56 multicenter clinical trials 56 Zybrestat 56 MEK inhibitor 56 motesanib 56 BYDUREON 56 Pivotal Phase III 56 Insegia 56 AVADO 56 RoACTEMRA 56 ALN TTR# 56 APPRAISE 56 Tyvaso 56 FTY# 56 sorafenib Nexavar 56 PD LID 56 ZYBRESTAT 56 lintuzumab 56 Genz # 56 TG# [003] 56 European Sepsis Trial 56 OMP #M# 56 IMC #B 56 TLK# 56 RSD# 56 Clevudine 56 LEUKINE 56 Phase 56 methylnaltrexone 56 Saphris 56 triphendiol 56 dosing regimens 56 relapsing remitting multiple sclerosis 56 CA4P 56 Onalta ™ 56 AVE# 56 PMA submission 56 nalmefene 56 investigational hepatitis C 56 abiraterone 56 alemtuzumab Campath 56 Technosphere Insulin 56 EVIZON 56 Omnitarg 56 rhThrombin 56 Ceflatonin R 56 XmAb# 56 Azilect ® 56 VEGF inhibitor 56 Carfilzomib 56 NEBIDO 56 Yondelis 56 rNAPc2 56 rhC1INH 56 oral cladribine 56 Phase III Trial 56 Tavocept 56 Roche Chugai s 56 Replagal 56 voclosporin 56 tolerability 56 Ilaris 56 oxymorphone ER 56 Amplimexon 56 immunomodulatory therapy 56 PEARL SC 56 PANVAC VF 56 eniluracil 56 vorinostat 56 tesmilifene 56 Atrasentan 56 Sebivo 56 ELACYT 56 nab paclitaxel 56 initiate Phase 2b 56 acyclovir Lauriad R 56 Cloretazine 56 Neupro 56 TMC# C# 56 lorvotuzumab mertansine 56 IIa clinical trial 56 Rhucin 56 dirucotide MBP# 56 CUSTOM III 56 docetaxel Taxotere R 56 Xinlay 56 vidofludimus 56 Cloretazine ® 56 maribavir 56 oral FTY# 56 AZD# 56 EDEMA3 56 CEQ# 56 Targretin 56 Relistor 56 celgosivir 56 Phase 2b monotherapy 56 preclinically 56 Indiplon 56 Panzem 56 velafermin 56 Sulonex 56 GVAX 56 Tanespimycin 56 atacicept 56 INTERCEPT platelets 56 regorafenib 56 dosing cohort 56 ambrisentan 56 cathepsin K inhibitor 56 Pimavanserin 56 randomized multicenter Phase III 56 Serdaxin 56 Onyx Pharma 56 iloperidone 56 Japanese Encephalitis vaccine 56 ATHX 56 Aptivus 56 rilonacept 56 Pazopanib 56 Troxatyl 56 PRIMO CABG 56 NUVIGIL 56 GTC recombinant human 56 receptor tyrosine kinase inhibitor 56 ATryn R 56 vemurafenib 56 Levadex 56 lasofoxifene 56 refractory CLL 56 Phase 1b clinical trials 56 zafirlukast 56 amrubicin 56 SILENOR TM 56 selective androgen receptor modulator 56 Cellegesic 56 Bepreve 56 AeroLEF TM 56 Trizytek 56 LEP ETU 56 Northera 56 fostamatinib 56 Cimzia ® certolizumab pegol 56 multicentre randomized 56 interferon beta 1b 56 TPI ASM8 56 pazopanib 56 IPLEX 56 angiogenesis inhibitor 56 LibiGel ® 56 sunitinib 56 Adcirca 56 SILENOR 56 monotherapy 56 masked placebo controlled 56 Raptiva ® 56 maximally tolerated dose 56 diarrhea predominant irritable 56 APD# 56 HGS ETR1 56 dyskinesia PD LID 56 ThGRF 56 subcutaneous formulation 56 Mepact 56 MoxDuo IR 56 Ceplene R 56 Mylotarg 56 Locteron 56 canakinumab 56 VFEND 56 Satraplatin 56 CLIRS trial 56 multicenter study 56 MAGE A3 ASCI 56 Marketing Authorization Application MAA 56 OncoGel 55 ganaxolone 55 MONOVISC 55 Microplasmin 55 Phase IIb Trial 55 Personalized Immunotherapy 55 Zenvia ™ 55 Phase III Trials 55 iclaprim 55 Phase III Pivotal 55 M6G 55 luliconazole 55 Ophena TM 55 linaclotide 55 cancer immunotherapies 55 tafamidis 55 NDA resubmission 55 DYNEPO 55 GW# [003] 55 Myocet 55 outlicensed 55 EchoCRT 55 Degarelix 55 indacaterol 55 histone deacetylase HDAC inhibitor 55 Vertex telaprevir 55 MabCampath 55 satraplatin 55 MabThera rituximab 55 tonabersat 55 lapatinib Tykerb 55 indiplon 55 QNEXA 55 Nexavar 55 Evoltra 55 Itopride 55 disease modifying 55 Azedra 55 Afresa 55 MYDICAR 55 Tracleer ® 55 Zoraxel 55 clazosentan 55 Qnexa 55 Abiraterone acetate 55 Promacta 55 registrational trials 55 Loramyc 55 SEBIVO 55 PEG INTRON 55 Cloretazine R VNP#M 55 HepeX B 55 regadenoson 55 temozolomide 55 Galvus 55 Emselex 55 Tovaxin 55 PRE SURGE 55 JZP 55 investigational humanized monoclonal antibody 55 preclinical toxicology 55 gaboxadol 55 Augment Injectable 55 JAK2 inhibitor 55 Onconase 55 Huntexil 55 ruboxistaurin 55 bioequivalence studies 55 ACV1 55 Clolar ® 55 Bezielle 55 peginesatide 55 Iluvien ® 55 milnacipran 55 Nexavar ® 55 efficacy 55 relapsing multiple sclerosis 55 TACI Ig 55 UPLYSO 55 blinded placebo controlled 55 Votrient 55 ASONEP 55 talactoferrin 55 Tracleer R 55 mTOR inhibitor 55 Prosaptide 55 sitaxsentan 55 unblinding 55 Rebif ® 55 Xanafide 55 phase IIb III 55 ThermoDox ® 55 Ophena 55 TroVax 55 UCB Cimzia 55 Onbrez Breezhaler 55 lupus nephritis 55 Pfizer Sutent 55 BRIM2 55 double blind placebo 55 Moxatag 55 Dextofisopam 55 visilizumab 55 Traficet EN 55 Ceplene TM 55 MERLIN TIMI 55 Ranexa 55 StemEx 55 Aurexis 55 subcutaneously administered 55 MDV# 55 Febuxostat 55 administered subcutaneously 55 Sprycel 55 sNDA submission 55 bioequivalence 55 GV# [001] 55 Tolamba 55 aclidinium bromide 55 MIST II 55 CHAMPION PCI 55 nalbuphine ER 55 JAK3 inhibitor 55 Iloperidone 55 ceftaroline 55 Augment Bone Graft 55 SEPET TM 55 Clolar 55 SPIRIT III 55 HuLuc# 55 relapsed refractory multiple myeloma 55 Benlysta belimumab 55 evaluating tivozanib 55 ascending doses 55 Esbriet 55 experimental hepatitis C 55 Rhucin ® 55 vascular disrupting agent 55 INT# [002] 55 orally bioavailable 55 oral rivaroxaban 55 Proellex TM 55 tanezumab 55 Zelrix 55 randomized multicenter trial 55 TEMSO 55 Valtropin 55 Aplidin 55 microplasmin 55 Aclidinium 55 Sunovion 55 Mycograb 55 Genasense 55 Dasatinib 55 febuxostat 55 phase III isavuconazole 55 FlutiformTM 55 Elocalcitol 55 Avastin bevacizumab 55 palonosetron 55 Factor Xa inhibitor 55 BNC# 55 Spiegelmer ® 55 blinded randomized placebo controlled 55 polymerase inhibitor 55 TG# [001] 55 LCP Tacro 55 refractory metastatic colorectal cancer 55 SAR# [004] 55 EGS# 55 Phase III placebo controlled 55 Loramyc ® 55 DEB# 55 multicenter placebo controlled 55 PS# [001] 55 canagliflozin 55 Ridaforolimus 55 senicapoc 55 VNP#M 55 ceftobiprole 55 denufosol 55 HQK 55 Board DSMB 55 Immunogen 55 PEGylated interferon beta 1a 55 Sapacitabine 55 bifeprunox 55 prucalopride 55 Hematide 55 BENLYSTA 55 perifosine 55 Clavis Pharma 55 Orathecin 55 Vilazodone 55 ABSORB trial 55 Hepatocellular Carcinoma HCC 55 PF # [001] 55 temsirolimus 55 Vicinium TM 55 ILLUMINATE 55 uric acid lowering 55 crofelemer 55 FM VP4 55 II Clinical Trial 55 Serdolect ® 55 Pivotal Clinical Trial 55 Balaglitazone 55 Glybera R 55 Afrezza 55 belinostat 55 PSMA ADC 55 oral methylnaltrexone 55 PCA3 test 55 RhuDex TM 55 Degludec 55 trabectedin 55 Atu# 55 Syncria 55 CLARITY study 55 Actilon 55 Vertex Pharma 55 Elvitegravir 55 tocilizumab 55 Azixa 55 Horizant 55 linagliptin 55 TRO# 55 myelofibrosis 55 Cethromycin 55 Mozobil 55 CRLX# 55 Drug Eluting Stent System 55 IV APAP 55 Octreotide 55 Clonicel 55 macitentan 55 CytoFabTM 55 TEMODAL 55 QuatRx 55 zanolimumab 55 RSR# 55 NOXAFIL 55 etanercept Enbrel 55 pirfenidone 55 Novolimus 55 CAPHOSOL 55 ToGA 55 Selzentry 55 amifampridine phosphate 55 naproxcinod 55 TRISENOX 55 Tarvacin TM 55 ALTU 55 Marketing Authorisation Application MAA 55 AIMM trial 54 preclinical efficacy 54 Vicriviroc 54 Dapagliflozin 54 Campath 54 Phase III psoriasis 54 mGluR5 NAM 54 Serada 54 SCH # 54 fenretinide 54 Reolysin 54 Stedivaze 54 Q#IR 54 eculizumab 54 Plenaxis TM 54 pediatric acute lymphoblastic 54 Zavesca 54 MDS AML 54 Soliris TM eculizumab 54 Shigamabs ®

Back to home page